Study #2022-0941
A phase Ib trial of Azacitidine, Venetoclax and Allogeneic NK cells for Acute Myeloid Leukemia (ADVENT-AML)
MD Anderson Study Status
Enrolling
Treatment Agent
Azacitidine, Venetoclax, NK Cells
Description
To learn if adding a healthy person's natural killer (NK) cells to the combination of Azacitidine and Venetoclax can help to control AML. NK cells are cancer- and infection-fighting immune cells.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Acute Myeloid Leukemia
Study phase:
Phase I
Physician name:
Abhishek Maiti
Department:
Leukemia
For general questions about clinical trials:
1-877-581-3446
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.